Pfizer Earnings: What The Street And The Crowd Expect

Pfizer Inc. PFE will announce its first quarter financial results on Tuesday morning, before the market opens.

According to Estimize, Wall Street analysts and the crowd pretty much agree regarding expectations. The former model EPS of $0.50 on revenue of $10.808 billion, while the latter projects EPS of $0.51 on revenue of $10.95 billion.

These estimates imply a decline from both the $0.57 EPS reported in the same quarter last year, and from the $0.54 EPS registered last quarter. The company did not provide guidance for the first quarter.

Related Link: Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

The graph below illustrates Pfizer’s history of estimates versus actual earnings:

It's also possible to see how estimates have changed over time:

As the graph shows, the Street’s expectations fell over January and February and, after recuperating slightly in early March, they remained in the $0.50 level.

The crowd’s expectations were more consistent over the quarter, with only one bump up last Friday.

The Experts Say…

In a recently issued report, Morgan Stanley provided a preview of major pharmaceutical companies’ first quarter results and listed key events for the second quarter.

The analysts say they model EPS of $0.48, below consensus. In the second quarter, they will be looking at the “Potential Ibrance next data readout (PALOMA-2 interim analysis 2Q-3Q:15), 2) Trumenba (menincococcal vaccine): Potential ACIP vote on routine use in adolescents (ACIP 2015 meetings are Feb. 25–26, Jun. 24–25, and Oct. 21–22), 3) Oncology business analyst meeting at ASCO in June, including Merck KGaA PD-L1 data in ovarian cancer.”